MarketMoodz
OS Therapies' OST‑HER2 Data Bolsters Regulatory Push
OS Therapies reported that its Phase 2b OST‑HER2 trial in pulmonary metastatic osteosarcoma showed statistically significant overall survival at the 2.5‑year mark, strengthening the company’s case for regulatory filings across multiple jurisdictions. The company says regulators in Europe and Australia have aligned on three‑year overall survival as primary evidence for conditional approvals, while the U.S. path is being discussed ahead of planned FDA and MHRA meetings; these claims have not been independently verified.
Key Takeaways
- Company-reported 2.5‑year overall survival (OS) for OST‑HER2 was 75% versus a 47% historical control (p=0.003).
- Two‑year OS in the OST‑HER2 cohort was reported at 75% versus 60% (p=0.034), with no new patient deaths between 2 and 2.5 years, per the company.
- OS Therapies says the EMA and Australia’s TGA accept three‑year OS as primary evidence for conditional marketing authorizations and a rolling review is underway in Europe.
- OST Therapies is planning U.S. and U.K. regulatory meetings — a Type B pre‑BLA and a Type C FDA meeting and an MHRA Scientific Advice meeting — and expects three‑year data in early Q4 2026 to support filings.
- Claims are based on company statements and anonymous sources and could not be independently verified; investors should await primary data or a peer‑reviewed release.
People Involved
- No specific individuals mentioned
Entities Involved
- OS Therapies Inc. (OSTX)Biotech sponsor and developer of OST‑HER2
- OST‑HER2Investigational therapy for pulmonary metastatic osteosarcoma
- European Medicines Agency (EMA)Regulatory authority reportedly aligned on three‑year OS for conditional marketing authorizations
- Therapeutic Goods Administration (TGA)Australia’s regulator reportedly aligned on three‑year OS as primary evidence
- U.S. Food and Drug Administration (FDA)Regulatory authority — company plans Type B pre‑BLA and Type C meetings to discuss Accelerated Approval
- Medicines and Healthcare products Regulatory Agency (MHRA)UK regulator — company plans a Scientific Advice meeting
MarketMoodz Analysis
For investors, a statistically significant overall survival signal at 2.5 years would materially de‑risk OSTX if validated by primary data: three‑year OS as an agreed primary endpoint across the EMA and TGA could let the company pursue conditional approvals in major markets sooner and shorten the commercialization timeline if regulators accept the dataset. The market reacted: OSTX reportedly rose about 8.29% to $2.03 in premarket trading on the news, but that move rests on company disclosures that have not been independently confirmed.
Caution is warranted. The reported 75% vs 47% comparison uses a historical control, which introduces bias risks versus a randomized comparator; p‑values (p=0.003 at 2.5 years, p=0.034 at 2 years) look strong but require context on sample size, censoring and maturity. The company also cites a pharmacodynamic immune‑response biomarker as a surrogate efficacy endpoint — a potentially useful regulatory lever but one that needs validation and explicit regulator acceptance before it can replace hard endpoints in filings.
What to watch next: demand a primary data release or conference presentation detailing patient numbers, censoring and the biomarker analysis; monitor the outcomes of the planned FDA, MHRA and EMA engagements (early June 2026 meetings are reported); and track the three‑year OS readout expected in early Q4 2026 plus any formal rolling‑review communications from European regulators. Until those items arrive, the story remains promising but unconfirmed, and the typical risks — delayed meetings, additional data requests, and competition in osteosarcoma — could still compress upside.
Source: Original Article